Investors

Cerenome (Nasdaq: CNSY), formerly Plus Therapeutics, Inc. (Nasdaq: PSTV), is a CNS oncology company advancing precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system (CNS) cancers. The Company combines proprietary diagnostic, therapeutic, and AI technologies into an integrated CNS oncology platform designed to improve how CNS cancers are detected, treated, and understood.

By connecting diagnostics, therapeutics, and longitudinal patient data within a single organization, Cerenome is building a proprietary learning platform designed to strengthen clinical decision-making, accelerate therapeutic development, and continuously improve patient care over time. Cerenome's business is built on three complementary platforms:

• CNSide® Diagnostics – A commercially available cerebrospinal fluid (CSF)-based platform for the detection, molecular characterization, and longitudinal monitoring of CNS cancers through tumor cell enumeration (TCE), immunocytochemistry (ICC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS).
• REYOBIQ™ (rhenium Re186 obisbemeda) – An investigational targeted radiotherapeutic being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancer, designed to deliver targeted radiation directly to CNS tumors while limiting systemic exposure.
• Data and AI – A proprietary artificial intelligence initiative designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology, accelerate therapeutic development, and enhance clinical decision-making across the Company's diagnostic and therapeutic platforms.

Each platform reinforces the others by generating proprietary clinical, molecular, imaging, and treatment data that strengthen diagnostic insights, inform therapeutic development, and expand the capabilities of Cerenome's AI platform over time.

Headquartered in Houston, Texas, Cerenome integrates commercial diagnostic operations, clinical-stage therapeutic development, and specialized laboratory and manufacturing capabilities to advance its integrated CNS oncology platform.

Houston provides strategic access to leading cancer centers, research institutions, and funding organizations, including the Cancer Prevention and Research Institute of Texas (CPRIT), which has supported multiple Company therapeutic development programs.

By integrating precision diagnostics, targeted therapeutics, proprietary data assets, and artificial intelligence, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term value through commercial diagnostics, therapeutic innovation, and data-driven insights.